Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Covered in this story
Analyst targets on Hims Hers Health Inc Class a
- Truist Securities: $28.5 → $32 by Oct 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $HIMS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Hims Hers Health Inc Class a →Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.